NCT06095713 - German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Fabry Disease

Interventions

DRUG

Pegunigalsidase-alfa

Standard of care

Trial Locations (8)

RECRUITING

Fabry disease center Berlin - Charité - Universitätsmedizin Berlin, Berlin

RECRUITING

Fabry disease center Cologne, Universitätsklinikum Köln, Cologne

RECRUITING

Fabry disease center Hamburg, Universitätsklinikum Hamburg, Hamburg

RECRUITING

Fabry disease center Hannover, Universitätsklinikum Hannover, Hanover

RECRUITING

Fabry disease center Mainz, Universitätsmedizin Mainz, Mainz

RECRUITING

Fachinternistische Gemeinschaftspraxis, Müllheim, Müllheim

RECRUITING

Fabry disease center Münster, Universitätsklinikum Münster, Münster

RECRUITING

Fabry disease center Würzburg, Universitätsklinikum Würzburg, Würzburg